Chelation therapy is largely unknown, ignored, and condemned by conventional medicine, with organizations like the American Heart Association and the American Medical Association have openly denounced chelation therapy as being ineffective and unproven as a result of several reasons, most of which are influenced by politics. The main reason why chelation therapy is not endorsed by the majority of those in conventional medicine is because it represents a threat to the conventional medicine establishment. This threat is not one of corruption or a threat to patient's health, but a threat of losing millions of dollars each year.



The many different organizations and people who are part of the treatment of cardiovascular ailments are paid billions of dollars each year, with each bypass surgery that is performed brining in between $25,000 and $50,000, and each angioplasty up to $15,000. The variety of drugs that lower cholesterol, normalize heart rhythm, relieve pain, and reduce high blood pressure, along with the numerous consultations, tests, retests, and exams add up to hundreds of millions of dollars. Chelation therapy poses and economic threat, bringing on itself the condemnation of the conventional medical world.

Pharmaceutical companies go along with this condemnation toward chelation therapy in order to keep EDTA chelation therapy from becoming main stream. They do this because EDTA chelation has recently lost its patent, with no pharmaceutical company wanting to undertake the huge amounts of money that it would take to document the therapeutic effects of chelation adequately enough so that it may be recognized by the FDA.

Also, because there are hundreds of products that have been developed for treating the many symptoms of heart disease, which include hypertension, angina, and arteriosclerosis, just to name a few, developing a product that could prevent or at least improve a condition of heart disease would mean that the need for these other medications would disappear, which results in a huge financial loss for pharmaceutical companies.

The point of this is that despite the apparent safety and effectiveness of chelation therapy in preventing and reversing the effects of heart disease, it is being held back because of money and politics. This is extremely unfortunate for those people who suffer from heart disease, when considering that doctors, pharmaceutical groups, and other that make up the medical establishment should make their patients' health their first priority, rather than how much money they could potentially lose by suggesting treatment options like chelation therapy.

EDTA has been shown to help with scleroderma, rheumatoid and osteoarthritis, along with vascular disease and heavy metal poisoning. It has been shown to be after than other chelating agents that have been used for rheumatoid diseases, with studies proving that it chelates unwanted calcium that has been deposited in joint areas, tendons, and muscles.

All in all, EDTA chelation therapy has been shown to be extremely safe, with virtually no side effects being discovered and its long term use has not resulted in any documented severe side effects. Like any other kind of therapy, there are some individuals who should consult their health practitioner before considering EDTA chelation therapy. These include pregnant women and those with impaired kidney function.